Roche, a biotechnology company with a focus on diagnostics, has announced that its AI-enabled continuous glucose monitoring system has gained Conformité Européenne (CE) marking. This provides diabetic patients in Europe with a new option to measure and control their blood glucose levels, with the added benefit of an AI-powered predictive tool that can give patients a forecast of their blood glucose levels for up to two hours using a connected mobile app. This new tool could provide diabetic patients with a greater degree of blood glucose control and prevent dangerous hypoglycemic and hyperglycemic events.
Ensuring patient control of blood glucose levels is essential to managing both type 1 and type 2 diabetes. Currently, available continuous glucose monitoring systems provide real-time updates and some degree of connectivity to smartphone applications for patients’ ease of use. In addition to real-time updates, Roche’s AI innovation provides patients with two hours of glucose trends, warnings for hypoglycemia within 30 minutes, and predictions for dangerous overnight hypoglycemic events.
GlobalData forecasts that the continuous glucose monitors market will have sales of $4.7bn in 2023, increasing at a compound annual growth rate of 3.59% to $6.7bn in 2033. This market growth is fueled by the growing population of diabetics worldwide, continued demand for ease of use in the diabetic population, and new products entering the market. Innovations, such as those developed by Roche, will contribute to this growth and provide new options to the growing population of diabetics.
Roche’s innovation in continuous glucose monitoring and predictive AI provides a new, effective option for diabetics looking for greater control over their blood glucose levels. The adoption of AI in the continuous glucose monitoring space looks to be a positive force for patients, as it will reduce concerns regarding hypoglycemic episodes and provide additional information to help patients better manage their diabetes.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
<!–
–>
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.medicaldevice-network.com/analyst-comment/roche-continuous-glucose-monitor-ai-management-diabetic-patients/